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Objective: To evaluate the effects of altitude travel on exercise performance and symptoms 
in lowlanders with COPD.
Design: Randomized crossover trial.
Setting: University Hospital Zurich (490 m), research facility in mountain villages, Davos 
Clavadel (1,650 m) and Davos Jakobshorn (2,590 m).
Participants: Forty COPD patients, Global Initiative for Obstructive Lung Disease (GOLD) 
grade 2–3, living below 800 m, median (quartiles) age 67 y (60; 69), forced expiratory volume 
in 1 second 57% predicted (49; 70).
Intervention: Two-day sojourns at 490 m, 1,650 m, and 2,590 m in randomized order.
Outcome measures: Six-minute walk distance (6MWD), cardiopulmonary exercise tests, 
symptoms, and other health effects.
Results: At 490 m, days 1 and 2, median (quartiles) 6MWD were 558 m (477; 587) and 577 m 
(531; 629). At 2,590 m, days 1 and 2, mean changes in 6MWD from corresponding day at 490 m 
were -41 m (95% CI -51 to -31) and -40 m (-53 to -27), n=40, P,0.05, both changes. At 1,650 m, 
day 1, 6MWD had changed by -22 m (-32 to -13), maximal oxygen uptake during bicycle exer-
cise by -7% (-13 to 0) vs 490 m, P,0.05, both changes. At 490 m, 1,650 m, and 2,590 m, day 1, 
resting PaO
2
 were 9.0 (8.4; 9.4), 8.1 (7.5; 8.6), and 6.8 (6.3; 7.4) kPa, respectively, P,0.05 higher 
altitudes vs 490 m. While staying at higher altitudes, nine patients (24%) experienced symptoms 
or adverse health effects requiring oxygen therapy or relocation to lower altitude.
Conclusion: During sojourns at 1,650 m and 2,590 m, lowlanders with moderate to severe 
COPD experienced a mild reduction in exercise performance and nearly one quarter required 
oxygen therapy or descent to lower altitude because of adverse health effects. The findings may 
help to counsel COPD patients planning altitude travel.
Registration: ClinicalTrials.gov: NCT01875133
Keywords: CPET, cardiopulmonary exercise testing, acute mountain sickness, hypoxia, adverse 
health effects, dyspnea, altitude illness, arterial blood gas analysis, pulmonary function
Introduction
COPD is characterized by chronic airflow obstruction related to airway inflammation, 
remodeling, and parenchymal destruction of the lung.1 This causes dyspnea, exercise 
limitation, and an impaired quality of life. Worldwide, more than 200 million tourists 
are estimated to visit altitudes over 1,500 m each year.2 Among them, many patients 
with COPD are expected to experience adverse health effects including acute mountain 
sickness,3 excessive dyspnea, and impairment of exercise performance during every-
day activities when exposed to hypobaric hypoxia during altitude sojourns. However, 
Correspondence: Konrad e Bloch
Department of respiratory Medicine, 
University hospital of Zurich, 
raemistrasse 100, 8091 Zurich, 
switzerland
Tel +41 44 255 3828
Fax +41 44 255 4451
email konrad.bloch@usz.ch 
Journal name: International Journal of COPD
Article Designation: Original Research
Year: 2018
Volume: 13
Running head verso: Furian et al
Running head recto: Exercise performance in lowlanders with COPD
DOI: 173039
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
4.
20
0.
17
.4
2 
on
 0
4-
Ja
n-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3530
Furian et al
whether and to which extent impaired pulmonary gas 
exchange, reduced muscle strength, and cardiovascular and 
other limitations affect well-being and physical performance 
in COPD patients traveling to high altitude has not been 
extensively studied. In a recent physiological investigation, 
we observed a reduction of submaximal constant load bicycle 
exercise by about one half due to systemic and cerebral hypox-
emia in a group of COPD patients at 2,590 m compared with 
the performance at their low altitude residence.4 To provide 
a scientific basis to counsel COPD patients planning altitude 
sojourns, the current study evaluated the effect of travel to 
altitudes of 1,650 and 2,590 m for a total of 4 days on exercise 
performance, general well-being, and several other outcomes 
in lowlanders with moderate to severe COPD.
Methods
study design and setting
This randomized crossover trial evaluated the effect of a 
4-day sojourn at moderate altitude on exercise performance, 
symptoms, and several physiological outcomes in patients 
with stable COPD, Global Initiative for Obstructive Lung 
Disease (GOLD) grades 2–3, living below 800 m. The studies 
were performed from June to August 2013 in Zurich (490 m, 
1,608 ft, barometric pressure [PB] 719 Torr) and in Swiss 
alpine villages, Davos Clavadel (1,650 m, 5,413 ft, PB 628 
Torr) and Davos Jakobshorn (2,590 m, 8,497 ft, PB 562 Torr). 
Participants spent 2 days at each study location, in random 
order, to undergo outcome assessments. Some physiological 
outcomes evaluating gas exchange, cerebral blood flow, and 
cerebral and muscle tissue oxygenation as a part of the cur-
rent trial have been reported recently.4 Apart from baseline 
characteristics of study participants, the data presented here 
have not been published except previously in abstract form. 
The study was approved by the Cantonal Ethics Committee 
of Zurich (EK-2013-0088), subjects gave written informed 
consent, and the trial is registered at www.ClinicalTrials.
gov: NCT01875133.
Participants
Subjects with stable COPD, GOLD grade 2–3, diagnosed 
according to the GOLD guidelines (forced expiratory 
volume in 1 second [FEV
1
]/forced vital capacity [FVC] 
ratio ,0.7, FEV
1
 between 30% and 80% predicted), aged 18 
to 75 years, both sexes, living below 800 m, were invited to 
participate. Subjects with very severe COPD (FEV
1
 ,30% 
predicted), respiratory failure at lowland (PaO
2
 ,7.3 kPa or 
PaCO
2
 .6.0 kPa), or those with known previous intolerance 
of altitude 2,600 m or lower, a history of sleep apnea syn-
drome, or more than mild or inadequately controlled cardio-
vascular disease were excluded. Patients having traveled to 
altitudes .1,500 m for .2 days within 4 weeks prior to the 
study were also excluded.
randomization and intervention
Using a balanced block design, participants were randomized 
to one of the following four sequences of altitude expo-
sure with sojourns of 2 days at each location: Group A 
490/1,650/2,590 m; Group B 490/2,590/1,650 m; Group C 
1,650/2,590/490 m; Group D 2,590/1,650/490 m. Partici-
pants traveled by train and car between Zurich and Davos 
Clavadel and by cable car between Davos Clavadel and 
Davos Jakobshorn.
As a safety precaution, the protocol required that any 
patient with intolerable discomfort (according to the patient’s 
own subjective assessment), symptoms or signs of relevant 
intercurrent illness, such as a COPD exacerbation, new onset or 
unstable cardiovascular disease including uncontrolled hyper-
tension (systolic and/or diastolic blood pressure .220 and/
or .110 mmHg), neurological impairment, gastrointestinal 
symptoms requiring treatment, or severe hypoxemia (arterial 
oxygen saturation ,80% for .30 minutes) were withdrawn 
from the study, treated with oxygen and other measures as 
appropriate, and transported to low altitude. Maximal bicycle 
exercise tests to exhaustion were performed at 490 m and 1,650 
m, but for safety reasons, not at 2,590 m. Patients were asked 
to continue their regular medication during the study.
assessments
exercise tests, pulmonary function, and arterial blood 
gas analysis
Six-minute walk tests with monitoring of pulse oximetry 
(SpO
2
) were performed.5
Lung function studies including spirometry, body 
plethysmography (only at 490 and 2,590 m due to logistical 
constraints), diffusing capacity (Bodystik™ and Diffustik™, 
Geratherm Respiratory GmbH, Bad Kissingen, Germany), 
and nasal sniff inspiratory pressure (Morgan P max, Morgan 
Medical Ltd., Gillingham, UK) were performed 15 minutes 
after inhalation of a short-acting bronchodilator.6,7 Pulmonary 
volumes and flows were expressed in body temperature, 
pressure, and saturated conditions. Diffusing capacity was 
measured by the single-breath technique. To allow for con-
venient comparisons between values measured at 490 m, 
2,590 m, and predicted values for sea level, values measured 
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at 2,590 m were corrected for the lower PB at altitude by 
transforming the equation recommended to predict values 
at high altitude:8
 
[DLCO
altitude
 = DLCO
sea level
/(1 +0.00031*[PI, O
2
 -150])], 
and solving for DLCO
sea level
,  
 
[DLCO
sea level
 = DLCO
2,590 m
*(1 +0.00031*[PI, O
2
 - 150])], 
whereas PI, O
2
 at 2,590 m corresponds to 
108 mmHg.  
Cardiopulmonary cycle exercise tests were performed 
with a progressive ramp protocol to exhaustion9 at 490 m 
and 1,650 m. The target duration of the exercise test at 490 m 
was 8–12 minutes, and the slope (ie, increase in watts per 
minute) was selected accordingly, based on the individually 
predicted maximal work rate (Wmax). For each individual, an 
identical ramp protocol was applied at 490 m and 1,650 m. 
Ventilation, gas exchange, oxygen saturation, and electro-
cardiogram were recorded breath by breath (Ergostik™, 
Geratherm Respiratory GmbH). Radial artery blood was 
drawn at rest and during maximal exercise and analyzed 
immediately (RAPIDPOINT 405, Siemens Healthcare Diag-
nostics GmbH, Zurich, Switzerland). Maximal physiologic 
variables of exercise tests were defined as mean values during 
the final 30 seconds of maximal exercise. Patients indicated 
the perceived exertion on the Borg CR10 scale.10
Clinical examination, evaluation of acute mountain 
sickness (aMs), and dyspnea
A complete medical history was obtained. Physical exami-
nation included weight, height, blood pressure, pulse rate, 
and SpO
2
. Dyspnea was assessed by the modified Medical 
Research Council dyspnea score.11 AMS was assessed in 
the morning and evening by the Environmental Symptoms 
Questionnaire cerebral score (AMSc) comprising 11 questions 
on AMS symptoms rated from 0 (not at all) to 5 (extreme). The 
weighted sum of responses ranges from 0 to 5. Scores $0.7 
are considered to reflect clinically relevant AMS.12
Outcomes
The primary outcome was the change in the 6-minute walk dis-
tance (6MWD). Secondary outcomes were the oxygen satura-
tion by SpO
2
, heart rate, lung function, arterial blood gases, and 
measures derived from cardiopulmonary exercise testing.
sample size
Sample size estimation indicated that at least 36 participants 
were required to detect a minimally important difference 
in the 6MWD of 30 m (SD 55 m) with a power of 80%, 
alpha 0.05.13 To account for dropouts, 40 participants were 
included.
Blinding
Investigators analyzing the data were blinded to altitude and 
altitude exposure sequence.
statistical analysis
Due to non-normal distribution of the majority of the data, all 
variables were summarized by medians and quartiles. Overall 
effects were evaluated by Friedman ANOVA, and significant 
findings were further analyzed by post hoc analyses using 
Wilcoxon matched pairs tests. Effects of altitude exposure 
were evaluated by computing mean differences in outcomes 
with 95% CIs. The primary outcome was analyzed according 
to the intention-to-treat principle with missing data replaced 
by multiple imputations applying a multivariable regression 
model with baseline variables as independent predictors. 
Secondary outcomes were analyzed according to the per-
protocol principle on all available data. Regression analyses 
were used to separately assess the effect of altitude (1,650 m 
and 2,590 m vs 490 m) on the 6MWD while controlling for 
baseline characteristics and potential confounders. Age, 
sex, and all predictor variables for which univariate analy-
sis revealed an association with P,0.2 were entered into a 
subsequent multivariable model. A probability of P,0.05 
was considered as statistically significant.
Results
The study participant flow is shown in Figure 1. Of 191 
screened subjects, 139 refused to participate and 12 met 
exclusion criteria. Thus, 40 subjects were included and 
randomized and their primary outcome (6MWD) was 
analyzed according to the intention-to-treat principle. One 
patient each in groups A to C and two in group D required 
nocturnal supplemental oxygen because of severe hypox-
emia (as defined per protocol by a value of SpO
2
 ,80% 
for $30 minutes) or dyspnea. These subjects felt well there-
after and remained at altitude but were excluded from exer-
cise tests on the next day. Two subjects withdrew informed 
consent after baseline examination in Zurich and one refused 
to ascend to 2,590 m because of insomnia at 1,650 m. Thus, 
the per-protocol group consisted of 32 participants (Table 1). 
The age of patients ranged from 51 to 74 y, 25% were cur-
rent smokers, and the median FEV
1
 was 59% predicted. The 
most prevalent comorbidities were cardiovascular diseases. 
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The majority of participants (81%) used regular inhaled 
β-adrenergics or anticholinergics and 56% used inhaled 
glucocorticoids (Table 1).
Several participants experienced altitude-related adverse 
health effects. In addition to those mentioned above who 
were withdrawn because of severe hypoxemia, dyspnea, or 
other discomfort, patients had (on average) mild symptoms of 
AMS that were most pronounced on the first day at 2,590 m 
(Table 2). The incidence of clinically relevant AMS (AMSc 
score $0.7) on the first and second day at 1,650 m was 3% 
(1 out of 38) and 0%, and on the first and second day at 
2,590 m was 5% (2 out of 38) and 0% in patients ascending 
to higher altitudes. The combined incidence of any altitude-
related adverse health effect during the 4 days at altitude was 
24% (9 out of 38).
six-minute walk tests, pulmonary 
function, and arterial blood gases
The 6MWD and SpO
2
 at the beginning and end of the 
6-minute walk test were significantly reduced at 1,650 m 
and 2,590 m compared with those at 490 m, and the per-
ceived dyspnea at the end of the 6MWD was greater at 
higher altitudes compared with values at 490 m (Table 2 
and Figure 2).
Univariable regression analysis with the change in 
the 6MWD from 490 m baseline as the dependent vari-
able revealed that altitude, second vs first day at altitude, 
the 6MWD, FEV
1
, and DLCO at 490 m were significant 
predictors. In a multivariable analysis, maintaining age, 
sex, and variables with P,0.2 in univariable analysis in the 
model, significant independent predictors for the 6MWD 
were altitude 1,650 m (predicted mean change -17 m [95% 
CI -27 to -6 m], P=0.001) and 2,590 m (predicted mean 
change -37 m [95% CI -47 to -27 m], P,0.001). Additional 
independent predictors were the baseline value of the 6MWD 
(+0.8 m [+0.7 to +0.9], P,0.001) and FEV
1
 % predicted at 
490 m (+0.9 m [+0.1 to +1.7], P=0.029), while age (P=0.866), 
sex (P=0.333), and DLCO at 490 m (P=0.188) were not.
Spirometry revealed no significant changes in FVC and 
FEV
1
 (in liters) nor in their ratio over the course of the study 
???????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????
???????????
???????????
??????????
????????
??????????
????????
?????????
??????????
??????????
????????? ????????????????????????????????????
? ? ? ???????????
????????????????? ?????????????????
????????????????????
????????????????????
????????????????????
????????????????????
???????????????????????????????????????????????????????
??? ??? ??? ???
????????
Figure 1 Patient flow.
Notes: Of 191 eligible subjects, 40 were randomized into one of the four altitude exposure sequences (a–D) and included in the intention-to-treat analysis. Data from 32 
subjects were included in the per-protocol analysis.
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at the different altitudes (Table 3). FVC (in % predicted) 
tended to be minimally greater at 1,650 m compared with 
other altitudes. Static lung volumes (total lung capacity, 
residual volume) were not different at 2,590 m vs 490 m. 
Peak expiratory flow improved significantly with increasing 
altitude, and correspondingly, airway resistance was reduced 
at 2,590 m vs 490 m. There was a slight but statistically 
significant reduction in the DLCO corrected for hemoglobin 
and for the reduced PB at 2,590 m.
The arterial blood gas analysis revealed a mild to moderate 
hypoxemia that increased with altitude (Figure 2, Table 4). 
The alveolar–arterial PO
2
 gradient was elevated at 490 m and 
decreased slightly at higher altitudes but remained elevated. 
According to inclusion criteria, patients were normocapnic 
at 490 m and their PaCO
2
 was slightly reduced at higher 
altitudes with an associated increase in pH.
Cardiopulmonary exercise tests
Compared with 490 m, endurance time, Wmax, and maximal 
oxygen uptake (V′O
2
 normalized for weight) were all sig-
nificantly reduced at 1,650 m. The reduction in endurance 
time and thus Wmax was -7% (95% CI -13 to 0, P,0.01). 
The impairment in exercise performance at 1,650 m was 
associated with a reduced PaO
2
, SaO
2
, and alveolar–arterial 
PO
2
 gradient during maximal exercise; in addition, there was 
a lower PaCO
2
 and increased ventilatory equivalents for O
2
 
uptake and CO
2
 output (V′E/O
2
 and V′E/CO
2
) compared with 
490 m. Subjective perception of dyspnea and leg fatigue were 
similar at low and high altitude (Table 5).
Discussion
The results of the current randomized trial show that 
patients with moderate to severe COPD living below 800 m 
Table 2 six-minute walk test and clinical evaluation
490 m 1,650 m 2,590 m P-value
First day Second day First day Second day First day Second day
6-minute walk 
distance, m
534±93 547±93* 512±93*,# 525±93#,† 491±93*,#,†,‡ 504±93#,‡,¶ ,0.001
spO2, rest, % 94 (94; 96) 94 (93; 95) 92*
,# (91; 94) 93*,# (91; 95) 89*,#,†,‡ (88; 91) 90*,#,†,‡ (87; 92) ,0.001
spO2, end of 6MWT, % 90 (84; 92) 89 (83; 92) 84*
,# (78; 87) 85*,# (77; 87) 78*,#,†,‡ (73; 82) 77*,#,†,‡ (73; 82) ,0.001
Borg dyspnea 3.0 (2.0; 5.0) 3.0 (3.0; 4.5) 4.0 (2.0; 4.5) 4.0*,#,† (3.0; 5.5) 3.5 (3.0; 5.0) 4.0*,#,† (3.0; 6.0) 0.003
Borg leg fatigue 2.5 (2.0; 4.0) 3.0 (1.0; 5.0) 2.5 (1.5; 4.0) 3.0 (1.0; 4.0) 2.0 (0.8; 3.0) 3.0 (1.5; 3.0) 0.567
mMrC dyspnea score 1 (0; 1) 1 (1; 1) 1 (1; 1) 1 (1; 1) 1 (1; 1) 1# (1; 1) 0.045
acute mountain 
sickness score
0.00 (0.00; 0.09) 0.00 (0.00; 0.00) 0.00 (0.00; 0.18) 0.00 (0.00; 0.09) 0.18*,#,†,‡ (0.00; 0.35) 0.00¶ (0.00; 0.09) ,0.001
Weight, kg 77.3 (67.9; 87.4) 77.3 (68.2; 87.4) 78.2*,# (66.6; 88.6) 78.3*,# (67.4; 87.9) 78.3*,# (67.9; 88.0) 78.6*,# (67.5; 87.9) ,0.001
Notes: six-minute walk distance analyzed by the intention-to-treat analysis including all 40 randomized patients, values presented as mean ±sD. Other outcomes analyzed by 
the per-protocol approach including 32 patients, values presented as median (quartiles). P-values from Friedman anOVa. *P,0.05 vs 490 m day 1, #P,0.05 vs 490 m day 2, 
†P,0.05 vs 1,650 m day 1, ‡P,0.05 vs 1,650 m day 2, ¶P,0.05 vs 2,590 m day 1.
Abbreviations: 6MWT, 6-minute walk test; mMRC, modified Medical Research Council dyspnea score; SpO2, pulse oximetry.
Table 1 Characteristics of patients
Characteristic At baseline
Demographics and clinical characteristics
n, (men/women)
age, y
Current smokers, n (%)
smoking, pack-years
FeV1, % predicted (postbronchodilator)
gOlD grade 2, n (%)
gOlD grade 3, n (%)
Body mass index, kg/m2
mMrC score
mMrC score $2, n (%)
32 (19/13)
67 (60; 70)
8 (25)
43 (20; 69)
59 (51; 71)
20 (63)
12 (37)
27.1 (22.2; 29.2)
1.0 (1.0; 1.5)
8 (25)
Comorbidities, n patients (%)
arterial hypertension
Coronary artery disease and other  
cardiovascular diseases
Diabetes mellitus
Depression
Previous pulmonary embolism
Dyslipidemia
19 (59)
8 (25)
2 (6)
8 (25)
2 (6)
9 (28)
Medication, n patients (%)
Inhalation of topical corticosteroids
Inhalation of β-adrenergics
Inhalation of anticholinergics
Roflumilast
Diuretics
aCe-inhibitor or aT2 antagonist
β-blocker
Calcium channel blocker
lipid-lowering therapy
antidiabetics
antidepressants
Theophylline
antiplatelet therapy
Oral anticoagulation
antiarrhythmic therapy
18 (56)
26 (81)
26 (81)
1 (3)
7 (22)
17 (53)
8 (25)
6 (19)
7 (22)
2 (6)
7 (22)
1 (3)
7 (22)
3 (9)
1 (3)
Note: Values presented as median (quartiles) unless indicated otherwise.
Abbreviations: aCe, angiotensin-converting enzyme; aT2, angiotensin II receptor; 
FeV1, forced expiratory volume in 1 second; gOlD, global initiative for chronic 
obstructive lung disease; mMRC, modified Medical Research Council dyspnea score; 
Pack-years, sum of years smoked a packet of cigarettes per day.
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Figure 2 altitude-induced changes.
Notes: Dots represent mean differences and horizontal bars the 95% CIs, values are numerically indicated on the right. Altitude effect is significant when the zero value is 
not part of the 95% CI.
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experienced a mild reduction in the 6MWD by a mean of 41 m 
at 2,590 m and by 22 m at 1,650 m. At 1,650 m, bicycle exer-
cise tests revealed a mild reduction of maximal performance 
by 7% related to hypoxemia and ventilatory limitation. Over 
the course of the 4-day sojourn at higher altitude, 9 of the 
38 patients (24%) experienced symptoms of AMS, dyspnea, 
or severe hypoxemia that required oxygen therapy for safety 
reasons. The current results represent a valuable reference 
that might help to counsel COPD patients planning altitude 
travel and prevent adverse effects on their health.
Data on exercise performance of COPD patients traveling 
to altitude are scant. In a study by Kelly et al,14 18 COPD 
patients (mean FEV
1
 42% predicted) were transported by 
car from sea level to Mt Hutt (2,086 m) for a sojourn of few 
hours. Not all patients were able to complete the 6-minute 
walk, and their mean walk distance was reduced to less 
than half of that at sea level (from 467 to 245 m). In eight 
COPD patients (FEV
1
 25%–78% predicted) traveling from 
sea level to Mount Washington (1,920 m), Vermont, PaO
2
 
initially dropped from 8.8 to 6.8 kPa, but values increased 
to 7.3 kPa with acclimatization over 4 days; patients per-
formed mild treadmill exercise without notable problems.15 
In the Dutch Asthma Center Davos (1,560 m), 37 lowlanders 
with COPD (FEV
1
 63% predicted) underwent a 5-week 
Table 3 Pulmonary function
490 m 1,650 m 2,590 m P-value
First day Second day First day Second day First day Second day
FVC, l 3.3 (3.0; 3.9) 3.5 (3.1; 4.2) 3.4 (3.1; 4.2) 3.4 (3.0; 3.9) 3.3 (3.1; 4.1) 3.4 (3.2; 4.1) 0.199
FVC, % pred 92 (88; 109) 95 (90; 113) 99* (89; 111) 97 (91; 107) 95† (88; 105) 94† (88; 104) 0.034
FeV1, l 1.5 (1.3; 2.1) 1.6 (1.4; 2.1) 1.7 (1.4; 2.2) 1.6 (1.4; 2.1) 1.5 (1.4; 2.2) 1.6 (1.4; 2.2) 0.231
FeV1, % pred 59 (51; 71) 57 (52; 75) 62 (58; 73) 63 (55; 71) 57 (53; 69) 56 (54; 72) 0.107
FeV1/FVC, % 51 (47; 62) 51 (47; 63) 53 (46; 61) 53 (48; 62) 53 (46; 61) 53 (45; 61) 0.283
PeF, l 4.73 (3.96; 6.19) 4.73 (3.76; 6.24) 4.95*,# (4.08; 6.49) 5.20*,# (4.23; 6.70) 4.88†,‡ (3.93; 6.14) 4.95†,‡ (4.02; 6.24) ,0.001
PeF, % pred 68 (56; 83) 69 (55; 82) 74*,# (57; 88) 72*,# (62; 91) 71†,‡ (57; 84) 68†,‡ (57; 83) ,0.001
DlCO hb adj, 
mmol*min-1 kPa-1
4.48 (3.65; 7.05) 4.52 (3.62; 7.25) 4.48 (3.47; 6.75) 4.54 (3.46; 6.75) 4.38*,# (3.47; 6.60) 4.38* (3.65; 6.60) 0.025
DlCO hb adj, % pred 56 (45; 76) 57 (44; 76) 56 (44; 74) 58 (44; 75) 52*,# (45; 74) 54* (45; 73) 0.013
TlC, l 6.8 (5.9; 7.7) 6.9 (6.2; 7.7) – – 6.8 (6.1; 7.7) 6.8 (6.1; 7.8) 0.984
TlC, % pred 111 (99; 122) 110 (100; 120) – – 110 (100; 122) 111 (100; 123) 0.984
rV, l 3.23 (2.72; 3.60) 3.38 (2.66; 3.69) – – 3.34 (2.86; 3.68) 3.21 (2.76; 3.69) 0.395
rV, % pred 134 (119; 170) 139 (115; 166) – – 142 (121; 172) 136 (115; 168) 0.435
rV/TlC ratio 47 (41; 54) 46 (42; 55) – – 47 (41; 55) 46 (41; 54) 0.371
raw total, kPa*s/l 0.35 (0.26; 0.47) 0.35 (0.29; 0.47) – – 0.31*,# (0.24; 0.41) 0.33*,# (0.24; 0.44) ,0.001
raw total, % pred 117 (87; 155) 117 (95; 155) – – 102*,# (78; 135) 110*,# (80; 147) ,0.001
snIP, cmh2O 74 (59; 104) 78 (62; 94) 79 (66; 96) 80 (66; 101) 76 (51; 93) 81 (66; 91) 0.536
Notes: Median (quartiles), n=32. P-values computed by Friedman anOVa for overall effects. *P,0.05 vs 490 m day 1, #P,0.05 vs 490 m day 2, †P,0.05 vs 1,650 m day 1, 
‡P,0.05 vs 1,650 m day 2. DlCO hb adj is the diffusing capacity adjusted for reduced inspiratory PO2 at altitude and corrected for measured hemoglobin (see Methods).
Abbreviations: DlCO, diffusing capacity test; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow; RV, residual volume; SNIP, 
sniff nasal inspiratory pressure; TlC, total lung capacity.
Table 4 arterial blood gases
490 m 1,650 m 2,590 m P-value
ph 7.41 (7.39; 7.42) 7.44* (7.42; 7.45) 7.45*,† (7.43; 7.46) ,0.001
PaCO2, kPa 5.5 (4.9; 5.9) 5.0* (4.7; 5.3) 4.9* (4.6; 5.2) ,0.001
PaO2, kPa 9.0 (8.4; 9.4) 8.1* (7.5; 8.6) 6.8*
,† (6.3; 7.4) ,0.001
saO2, % 93 (93; 95) 91* (89; 92) 85*
,† (84; 89) ,0.001
hCO3
-, mmol/l 25.9 (24.5; 27.4) 25.0 (24.4; 25.5) 25.6† (25.2; 26.8) 0.006
Base excess, mmol/l 1.2 (0.9; 2.1) 0.7* (0.1; 1.4) 0.9 (0.3; 1.8) 0.037
DaaPO2,
25 kPa 4.5 (3.9; 5.4) 3.4* (2.5; 3.9) 3.1*,† (2.5; 3.4) ,0.001
hemoglobin, g/dl 15.0 (14.5; 15.2) 14.6 (14.1; 15.2) 14.8 (14.2; 15.5) 0.066
hematocrit, % 44.5 (43.0; 44.8) 43.0* (41.0; 44.5) 43.8† (42.0; 46.0) 0.015
Notes: Median (quartiles), n=32. Arterial blood gases were drawn in the morning after the first night at the corresponding altitude. P-values computed by Friedman anOVa 
for overall effects. *P,0.05 vs 490 m day 1, †P,0.05 vs 1,650 m day 1.
Abbreviation: DaaPO2, alveolar–arterial PO2 difference.
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rehabilitation training. Compared with baseline evaluation 
at sea level, their exercise capacity at arrival at 1,560 m was 
not significantly reduced and it increased over the course of 
rehabilitation.16 No other studies on exercise performance 
during intermediate or long-term altitude sojourns of COPD 
patients were identified.
Compared with the patients reported by Kelly et al,14 the 
participants in the current trial had a less pronounced reduc-
tion in the 6MWD, which might be due to less severe COPD 
in the current trial (FEV
1
 59% vs 42% predicted). Another 
explanation is the difference in the study design because half 
of the patients in the current trial already stayed for 2 days 
at 1,650 m before ascending further to 2,590 m (Figure 1), 
which might have led to improved physical performance at 
2,590 m by acclimatization.
We have previously reported a reduction of endurance 
time during submaximal cycle exercise by 54% in COPD 
patients at 2,590 m.4 Underlying mechanisms were combined 
effects of hypobaric hypoxia on dyspnea and pulmonary gas 
exchange with arterial and cerebral hypoxemia (measured 
by near-infrared spectroscopy), while ventilatory limitation 
seemed not to have played a predominant role. Because 
exercise intensity during a 6MWD is submaximal, we 
assume that similar mechanisms may have contributed to 
the impaired performance at higher altitudes compared 
with 490 m in COPD patients participating in the current 
study. In turn, during progressive maximal ramp exercise 
at 1,650 m, our results suggest that mechanical ventilatory 
limitation has contributed to the reduction in maximal work 
performance. Thus, the breathing reserve was reduced, and 
there was a greater ventilatory inefficiency evidenced by the 
increased ventilatory equivalents for both O
2
 uptake and CO
2
 
output (Table 3).
In the current patients, there were no relevant changes in 
static and dynamic lung volumes at 2,590 vs 490 m (Table 3). 
For comparison, previous studies in healthy individuals17 
and in patients with obstructive sleep apnea syndrome18 
ascending to 2,590 m have shown a slight reduction in FVC 
that was not associated with a change in inspiratory muscle 
strength and was therefore possibly related to subclinical 
interstitial fluid accumulation. In the current study, a larger 
interindividual variability of baseline lung function in the 
COPD patients may have reduced the power to detect minor, 
altitude-induced changes. However, the current patients 
having an already reduced diffusing capacity to nearly half 
of the predicted value at 490 m revealed a further decrease 
at 2,590 m (Table 3). This was associated with an increase 
in body weight, suggesting a possible interstitial pulmonary 
fluid accumulation as suspected in healthy individuals in 
previous studies.19,20
In addition to the impairment of pulmonary gas exchange 
and consecutive hypoxemia related to the airflow limitation 
and parenchymal destruction of the lung, a potential further 
cause of exercise limitation in COPD patients at altitude 
relates to an excessive rise in pulmonary artery pressure due 
to hypoxic vasoconstriction in the presence of some degree 
of preexisting pulmonary hypertension. In support of this 
hypothesis, echocardiographic studies performed at rest 
revealed an elevated pulmonary artery pressure at 2,590 m 
compared with that at 490 m.21
In this trial, 9 of the 38 randomized patients (24%) 
ascending to higher altitude suffered from adverse altitude-
related health effects including headaches and clinically 
relevant symptoms of AMS (5% at 1,650 m, 18% at 
2,590 m), and 13% had severe hypoxemia at 2,590 m that 
prompted us to administer supplemental oxygen. While 
symptoms of AMS might have been controlled by pain 
Table 5 Maximal exercise performance
Values at peak exercise 490 m 1,650 m
Time, min:sec 9:13 (7:45; 10:50) 8:41* (6:46; 10:38)
Work rate, watts 92 (73; 120) 82* (63; 120)
% predicted 75 (59; 94) 69* (59; 87)
heart rate, 1/min 127 (115; 138) 123 (115; 140)
% predicted 80 (75; 88) 80 (75; 88)
V′O2, l/min 1.21 (0.90; 1.43) 1.06 (0.88; 1.47)
% predicted 67 (54; 85) 63 (52; 86)
V′O2, ml/min/kg 15.9 (14.2; 19.8) 15.0* (12.5; 19.7)
% predicted 78 (61; 85) 65* (55; 90)
V′CO2, l/min 1.23 (0.90; 1.57) 1.10 (0.87; 1.54)
% predicted 43 (37; 52) 41 (29; 55)
respiratory exchange ratio 1.03 (0.93; 1.09) 1.03 (0.95; 1.12)
Breath rate, l/min 36 (29; 40) 36* (32; 40)
V′e, l/min 52 (40; 64) 53* (38; 66)
Br, % 20 (5; 30) 12* (-3; 21)
V′e/VO2 38.4 (33.6; 45.2) 42.0* (37.0; 48.3)
V′e/VCO2 37.6 (33.2; 43.8) 41.0* (36.8; 47.4)
Pulse oximetry, % 95 (88; 98) 90* (85; 95)
arterial ph 7.37# (7.34; 7.39) 7.40* (7.35; 7.42)
PaCO2, kPa 5.4
# (5.3; 5.8) 4.7* (4.4; 4.9)
PaO2, kPa 7.7
# (7.1; 9.7) 7.5* (6.5; 8.2)
saO2, % 92
# (88; 95) 89* (83; 90)
DaaPO2,
25 kPa 5.5# (3.6; 6.1) 3.7* (3.1; 4.6)
Borg Cr-10 dyspnea 5 (4; 7) 5 (4; 7)
Borg Cr-10 leg 3 (2; 5) 3 (1; 5)
Notes: Median (quartiles), n=31. Breathing reserve calculated by (MVV-V′e)/
MVV*100; *P,0.05 vs 490 m; #arterial blood gas analysis during maximal exercise 
was available in 31 patients at 1,650 m and in 12 patients at 490 m; changes in arterial 
blood gas between 490 and 1,650 m are presented for the 12 patients.
Abbreviations: Br, breathing reserve; DaaPO2, alveolar–arterial PO2 difference;
 
MVV, maximal voluntary ventilation; V′O2, oxygen uptake; V′CO2, carbon dioxide 
output; V′e, minute ventilation.
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suppressants and other drugs including acetazolamide or 
dexamethasone that are successfully used in healthy moun-
taineers suffering from AMS,22 we considered it unethical 
to expose the COPD patients to prolonged hypoxemia 
with SpO
2
,80%. The rules for administration of oxygen 
were arbitrary because there is no conclusive evidence to 
suggest that level and duration of hypoxemia represent 
an increased risk for COPD patients, some of them with 
cardiovascular comorbidities. It is conceivable, however, 
that the risk for relevant cardiac arrhythmias and possibly 
adverse cardiovascular events might have been elevated at 
2,590 m because we have previously observed a prolonga-
tion of the QT interval in patients with COPD during a stay 
at 2,048 m23 or with obstructive sleep apnea syndrome at 
2,590 m.24 Moreover, we suspect that those COPD patients 
who had severe hypoxemia would have developed more 
severe symptoms of AMS if they had stayed untreated at 
altitude for a longer time.
According to our study design, the order of exposure 
to the different altitudes was performed in random order 
to reduce the bias that might have been induced by a fixed 
sequence of stay at the three elevations. The fact that half of 
the patients had already spent 2 days at a higher altitude than 
that of their residence before assessments at 1,650 or 2,590 m, 
respectively (Figure 1), is a limitation that might have influ-
enced the incidence of AMS and other altitude-related 
adverse health effects by acclimatization. In particular, we 
cannot exclude that a direct ascent from 490 m to 2,590 m by 
all participants might have resulted in a higher incidence of 
AMS and other adverse outcomes. However, in multivariable 
regression analysis, the altitude exposure sequence was not an 
independent predictor of the 6MWD. Although a relatively 
large number of well-characterized COPD patients partici-
pated in the current study, it included patients with moderate 
to severe COPD only; therefore, our results might not apply 
to patients with very severe (FEV
1
,30% predicted) or only 
mild (FEV
1
.80% predicted) COPD.
Conclusion
The results of the current study demonstrate that lowlanders 
with moderate to severe COPD experience a modest decrease 
in the 6MWD when ascending for 2 days to 1,650 m and 
2,590 m and their maximal performance during bicycle 
exercise is decreased at 1,650 m due to hypoxemia and 
ventilatory limitation. Severe hypoxemia for prolonged 
time was prevented by oxygen administration. Therefore, 
more severe impairments and adverse health effects might 
have been avoided. Our data may serve as a valuable basis 
for counseling patients with COPD planning altitude travel 
taking the individual condition, the physical fitness, and 
comorbidities into account.
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